Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553248 | 1.00 | NPSR1 (0.51) | NPSR1ALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL2500094 | 1.00 | NPSR1 (0.51) | NPSR1ALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL2554674 | 0.77 | NPSR1 (0.51) | NPSR1ALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL773203 | 0.77 | NPSR1 (0.63) | NPSR1ALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL3402827 | 0.76 | MAPT (0.52) | NPSR1ALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL11464064 | 0.75 | NPSR1 (0.68) | NPSR1ALDH1A1MAPTL3MBTL1HPGD | |
| Bupranolol SCHEMBL29518497 | 0.74 | L3MBTL1 (0.63) | NPSR1MAPTL3MBTL1KMT2AMEN1 | |
| Bupranolol SCHEMBL6508337 | 0.74 | L3MBTL1 (0.63) | NPSR1MAPTL3MBTL1KMT2AMEN1 | |
| Bupranolol SCHEMBL123717 | 0.74 | L3MBTL1 (0.63) | NPSR1MAPTL3MBTL1KMT2AMEN1 | |
| Bupranolol SCHEMBL34061 | 0.74 | L3MBTL1 (0.63) | NPSR1MAPTL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552433-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | Algynomics Inc. (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011126910-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110245208-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-06 | — | — | US | claimed |
| EP-2552433-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | Algynomics Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-2552433-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | Algynomics Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011126910-A3 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011126910-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011126910-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245208-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | OPRL1, OPRD1, OPRK1 | NPSR1 274/4885ALDH1A1 1285/4885MAPT 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.